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Abstract
Background: Recent developments in radiotherapeutic technology have resulted in a new approach to treating
patients with localized lung cancer. We report preliminary clinical outcomes using stereotactic radiosurgery with
real-time tumor motion tracking to treat small peripheral lung tumors.
Methods: Eligible patients were treated over a 24-month period and followed for a minimum of 6 months.
Fiducials (3–5) were placed in or near tumors under CT-guidance. Non-isocentric treatment plans with 5-mm
margins were generated. Patients received 45–60 Gy in 3 equal fractions delivered in less than 2 weeks. CT
imaging and routine pulmonary function tests were completed at 3, 6, 12, 18, 24 and 30 months.
Results: Twenty-four consecutive patients were treated, 15 with stage I lung cancer and 9 with single lung
metastases. Pneumothorax was a complication of fiducial placement in 7 patients, requiring tube thoracostomy in
4. All patients completed radiation treatment with minimal discomfort, few acute side effects and no procedure-
related mortalities. Following treatment transient chest wall discomfort, typically lasting several weeks, developed
in 7 of 11 patients with lesions within 5 mm of the pleura. Grade III pneumonitis was seen in 2 patients, one with
prior conventional thoracic irradiation and the other treated with concurrent Gefitinib. A small statistically
significant decline in the mean % predicted DLCO was observed at 6 and 12 months. All tumors responded to
treatment at 3 months and local failure was seen in only 2 single metastases. There have been no regional lymph
node recurrences. At a median follow-up of 12 months, the crude survival rate is 83%, with 3 deaths due to co-
morbidities and 1 secondary to metastatic disease.
Conclusion:  Radical stereotactic radiosurgery with real-time tumor motion tracking is a promising well-
tolerated treatment option for small peripheral lung tumors.
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Introduction
Treatment options for medically inoperable patients with
lung cancer are limited. Poor outcomes with protracted
conventionally fractionated radiotherapy approaches
prompted researchers in the last decade to explore ways of
delivering high doses of radiation in shorter periods of
time [1]. Utilizing a body frame and abdominal compres-
sion to limit lung motion, small mobile lesions have been
treated with relatively tight margins (10 mm) [2]. This
enhanced accuracy has facilitated the safe, swift delivery of
highly effective doses of radiation to small discrete
peripheral lung tumors such as stage I lung cancer and
pulmonary metastases [3-13]. Recently updated outcomes
of a Phase I stereotactic body radiotherapy (SBRT) dose
escalation study confirm that abbreviated radiosurgery
treatment courses, in which doses in the range of 45 Gy to
60 Gy are delivered in less than 2 weeks, result in durable
local control rates ranging from 70 to 90% [14]. Such
favorable outcomes establish thoracic stereotactic radio-
surgery as a new radical treatment option for small
peripheral lung tumors.
The CyberKnife frameless image-guided robotic radiosur-
gery system (Accuray Incorporated, Sunnyvale, CA) has
been successfully employed at Georgetown University
Hospital to treat stationary extracranial tumors since early
2002 [15]. With the introduction of the Synchrony
motion tracking module, in mid 2004, tumors that move
with respiration have been treated without potentially
uncomfortable methods to compensate for respiratory
movement, such as stereotactic body frames with abdom-
inal compression devices and respiratory gating tech-
niques [16]. Synchrony, an automated CyberKnife image-
guidance subsystem, continuously points the robot-
mounted linear accelerator at lung tumors as they move
with uninhibited respiration during radiation delivery
[17]. We report preliminary clinical outcomes from 24
consecutive patients with single small peripheral lung
tumors radically treated using Synchrony real-time tumor
motion tracking.
Methods and materials
Eligibility
This study was approved by the hospital institutional
review board and all participants provided informed writ-
ten consent. The Georgetown University Hospital multi-
disciplinary thoracic oncology team evaluated patients.
Mandatory baseline studies included CT scans of the
chest, abdomen and pelvis with IV contrast, PET imaging
and routine pulmonary function tests (PFTs). Patients
with small peripheral pathologically confirmed inopera-
ble Stage I lung cancer or single pulmonary metastases
were treated. Tumors were considered small if the maxi-
mum diameter measured less than 4 cm and peripheral if
radical treatment was feasible without exceeding conserv-
ative maximum point dose limits to critical central nor-
mal tissues derived from historical data (Table 1).
Conventional thoracic irradiation was permitted if it was
delivered more than one year prior to stereotactic radio-
surgery and directed to a different lobe of the lung and/or
the extrapulmonary thoracic lymphatics (i.e., hilar, medi-
astinal and supraclavicular lymph nodes). Concurrent
and salvage systemic therapies other than gemcitabine
were also permitted.
Fiducial placement
Tracking based on translational and rotational target
information requires that a minimum of 3 non-collinear
fiducials be placed in such a way that they do not obscure
each other on the orthogonal images of the CyberKnife x-
ray targeting system. Therefore, 3 to 5 gold fiducials meas-
uring 0.8–1 mm in diameter by 3–7 mm in length (Item
351-1 Best Medical International, Inc., Springfield, VA)
were placed in or near the tumors under CT-guidance as
recently described [18].
Treatment planning
Fine-cut (1.25 mm) treatment planning CTs were
obtained 7–10 days after fiducial placement during a full
inhalation breath hold with the patient in the supine
treatment position. This short delay prior to imaging
allowed procedure-related hemorrhage to resolve and
limited post-CT fiducial migration. Gross tumor volumes
(GTV) were contoured utilizing lung windows. All critical
central thoracic structures (Table 1) and the lungs were
contoured. A treatment plan with a 5-mm margin on the
GTV for contouring and tracking uncertainty was gener-
ated using the TPS 5.2.1 non-isocentric, inverse-planning
algorithm with tissue density heterogeneity corrections
for lung based on an effective depth correction. Radical
doses of 45 to 60 Gy in three equal fractions of 15 to 20
Gy were prescribed to an isodose line that covered at least
95% of the planning treatment volume (PTV = GTV + 5
mm). In general, total doses closer to 45 Gy were pre-
scribed when concerns about the radiation tolerance of
adjacent critical structures arose and when patients were
felt to have severe cardiopulmonary dysfunction. The per-
centage of the total lung volume receiving 15 Gy or more
(V15) was limited to less than 15% in order to decrease
Table 1: Critical central thoracic structure point dose limits
Critical Structure Maximum Point Dose Limit 
(Gy) (total for 3 fractions)
Spinal cord 18
Left ventricle 18
Esophagus 24
Main bronchus 30
Trachea 30
Aorta 30Radiation Oncology 2007, 2:39 http://www.ro-journal.com/content/2/1/39
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the risk of clinically significant radiation pneumonitis or
pulmonary dysfunction.
Treatment delivery
The treatment course was completed in less than two
weeks. Prior to the initial treatment, each patient was eval-
uated with fluoroscopy to verify that the motion of the
fiducials chosen for tracking correlated with tumor
motion. Prophylactic corticosteroids were not adminis-
tered. Patients were placed supine and unrestrained on
the treatment table with their arms at their sides. They
wore a form-fitting vest upon which 3 red light-emitting
markers were attached on the surface of the patient's ante-
rior torso in the region of maximum respiratory excursion
of the chest and upper abdomen. These markers projected
to an adjustable camera array in the treatment room. Pre-
cise patient positioning was accomplished utilizing the
automated patient positioning system. Fiducials were
located using orthogonal x-ray images acquired with ceil-
ing-mounted diagnostic x-ray sources and corresponding
amorphous silicon image detectors secured to the floor on
either side of the patient.
Immediately prior to treatment delivery, an adaptive cor-
relation model was created between the fiducial positions
as periodically imaged by the x-ray targeting system and
the light-emitting markers as continuously imaged by the
camera array [17]. During treatment delivery the tumor
position was tracked using the live camera array signal
and correlation model, the linear accelerator was moved
by the robotic arm in real time to maintain alignment
with the tumor during uninhibited respiration. Fiducials
were imaged prior to the delivery of every third beam for
treatment verification and to update the correlation
model [16]. If fiducials were misidentified by the software
or the correlation model error exceeded 3 mm in two con-
secutive paired x-ray images, treatment was discontinued
and the correlation model rebuilt.
Follow-up studies
Patients were followed with physical examinations, CT
imaging and routine PFT's at 3, 6, 12, 18, 24 and 30
months. Complete response was defined as resolution of
the tumor on CT imaging and partial response as a
decrease in the tumor volume relative to the treatment
planning CT. Local and regional tumor recurrence was
defined as unequivocal tumor progression on CT imaging
within the treated lobe or regional lymph nodes, respec-
tively. Biopsy was recommended for pathologic verifica-
tion. Toxicity was scored according to the National Cancer
Institute Common Terminology Criteria for Adverse
Events, Version 3.0 [19].
Statistical analysis
Follow-up was determined from the date of the last treat-
ment. Two-sided Wilcoxon signed-ranks tests were used to
assess statistical significance (α = 0.05) of post-treatment
changes in forced expiratory volume in 1 sec (FEV1), total
lung capacity (TLC) and diffusing capacity of the lung for
carbon monoxide (DLCO) at 6 and 12 months.
Results
Patient and tumor characteristics
Twenty-four consecutive patients (10 men and 14
women) were treated over a 2-year period extending from
July 2004 to July 2006 (Table 2). The median follow-up
time among survivors is 12 months (range, 6–30
months). No patients were lost to follow-up. Seventeen
percent of patients received prior conventional thoracic
radiation. All but one patient had stopped smoking in the
distant past (> 3 years) or had never smoked. Nonetheless,
pulmonary dysfunction was the primary rationale for
non-surgical treatment among the stage I lung cancer
patients and 3 such patients required supplemental home
oxygen prior to receiving treatment. Sixty-seven percent of
the tumors involved the upper lobes. Fifteen were inoper-
able primary lung tumors (adenocarcinoma 7, NSCLC not
otherwise specified 5, squamous cell carcinoma 2 and typ-
ical carcinoid tumor 1) and 9 were single lung metastases
(NSCLC 5, esophagus 1, small bowel 1, renal 1 and cuta-
neous basal cell carcinoma 1). The mean maximum
tumor diameter was 2 cm (range, 0.9 – 3.5 cm).
Treatment characteristics
Three equal fractions of 15 to 20 Gy were delivered in an
average of 7 days (Table 3). Treatment plans were com-
posed of hundreds of pencil beams shaped using a single
20, 25 or 30-mm diameter circular collimator. The per-
centage of the total lung volume receiving 15 Gy or more
was low despite the radical treatment intent. On average,
55 paired x-ray images were taken each day to confirm the
accuracy of the correlation model. Twenty-five percent of
the patients received concurrent systemic therapy as previ-
ously described [20].
Table 2: Patient and Tumor Characteristics
Mean (Range)
Age (years) 70 (50 – 82)
Weight (lbs) 160 (118 – 285)
FEV1 (L) 1.47 (0.53 – 2.62)
% predicted FEV1 61 (26 – 121)
% predicted TLC 94 (69 – 136)
% predicted DLCO 61 (44 – 96)
Maximum Tumor Diameter (cm) 2.0 (0.9 – 3.5)
Gross Tumor Volume (cc) 8 (1 – 14)Radiation Oncology 2007, 2:39 http://www.ro-journal.com/content/2/1/39
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Complications
Pneumothorax either during or immediately following
fiducial placement was seen in 30% of patients, and 17%
of all patients required tube thoracostomy to correct clin-
ically significant pneumothorax. All patients completed
treatment without interruption. Following treatment,
acute toxicity consisting of mild brief fatigue was reported
in the majority of patients. Transient chest wall discom-
fort, typically lasting several weeks, developed in 7 of 11
patients with lesions within 5 mm of the pleura.
Grade III pneumonitis was observed in 2 patients (8%).
One of the patients received concurrent Gefitinib treat-
ment. She developed an infiltrate corresponding to the
high dose stereotactic radiosurgery volume and dyspnea
requiring temporary supplemental oxygen 4 weeks after
completing CyberKnife treatment. Her symptoms
resolved quickly with steroids and the discontinuation of
Gefitinib. The second patient, who had a history of exten-
sive conventional esophageal irradiation, was treated for a
single lung metastasis. He developed symptomatic infil-
trates largely confined to the conventional radiation vol-
ume following the initiation of salvage experimental
systemic therapy 10 months after radiosurgery. His symp-
toms resolved over several weeks on steroids and he dis-
continued supplemental oxygen.
Post-treatment pulmonary status
Among the entire group, no change was seen in FEV1 and
TLC at 6 and 12 months. A statistically significant decline
of 8% (from 61% to 53%; p = 0.002) and 10% (from 61%
to 51%; p = 0.01) in the mean % predicted DLCO was
seen at 6 and 12 months, respectively.
Tumor response
All tumor volumes were reduced on CT imaging at 3
months. Six-month CT scans were available for all 24
patients. Fourteen lesions continued to respond to treat-
ment, three of which had resolved completely. Ten lesions
were obscured by radiation fibrosis at 6 months and were
not clearly evaluable. At 12 months, 16 patients' CT scans
were available for review. Four of the evaluable lesions
had responded completely, two exhibited an excellent
partial response to treatment and eight, or 50% of the
evaluable lesions, were obscured by radiation fibrosis
which corresponded with the planned high-dose treat-
ment volume and consistently encompassed the fiducials
(Figure 1). Despite the development of significant radia-
tion fibrosis with time, it was clear that two single lung
metastases had progressed locally per CT imaging at 12
months (Table 4). Therefore, with a median follow-up of
12 months, the crude local control rate for the group is
92%. Consistent with other reports, local control was
100% for stage I tumors and lower (78%) for single lung
metastases (Table 5) [21].
Disease spread and survival
Regional lymph node failure was not observed in early
follow-up. Four patients with locally controlled single
lung metastases developed additional metastatic sites and
received salvage systemic therapy. Despite treatment one
patient died of progressive metastatic disease at 8 months.
A second single lung metastasis patient died of a myocar-
dial infarction at 11 months without evidence of local or
systemic disease. No stage I lung cancer patient developed
metastatic disease. However, 2 stage I lung cancer patients
died of comorbid illnesses (1 secondary to progressive
congestive heart failure at 6 months and 1 secondary to
progressive emphysema at 9 months). Therefore, with a
median follow-up of 12 months, the crude survival rate
for the group is 83%, with 3 deaths due to co-morbidities
and 1 secondary to metastatic disease. As expected, the
crude survival rate for patients with single lung metastases
was lower (Table 5) [21].
Discussion
In mid-2004 we initiated a frameless image-guided high-
dose fractionated stereotactic radiosurgery treatment pro-
tocol for patients with medically inoperable small periph-
eral stage I lung cancer and single small peripheral lung
metastases. Continuous tracking of respiratory tumor
motion with Synchrony and highly accurate beam align-
ment throughout treatment with the CyberKnife
prompted us to deliver dose distributions with tighter
margins than historically feasible (5 mm) [2]. Hundreds
of beams were used to produce a relatively high central
tumor dose and dose gradients that conformed closely to
the shape of the tumors [22]. Twenty-four patients have
been treated in 24 months without notable discomfort
during the treatment procedure. With a median follow-up
of 12 months the crude local control rate is 92% and there
have been no severe (grade IV) treatment-related compli-
cations or mortalities. Thus, we conclude that radical ster-
eotactic radiosurgery with real-time tumor motion
tracking and continuous beam correction utilizing the
CyberKnife system is a feasible, well-tolerated and highly
Table 3: Treatment Characteristics
Mean (Range)
Dose (Gy) 54 (45 – 60)
Biologic Effective Tumor Dose (BED Gy10) 150 (110 – 180)
Prescription Isodose Line (%) 80 (75 – 90)
Planning treatment volume coverage (%) 97 (95 – 100)
Number of beams per fraction 164 (87 – 270)
Number of paired x-ray verification
 images per fraction
55 (29 – 90)
Beam-on time (minutes) 82 (53 – 120)
Treatment course (days) 7 (3 – 11)
% Total lung volume receiving 15 Gy or more 7 (3 – 11)Radiation Oncology 2007, 2:39 http://www.ro-journal.com/content/2/1/39
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effective treatment option for small peripheral lung
tumors.
Despite promising early results, critical issues concerning
the evaluation of treatment efficacy and the possibility of
late complications have yet to be fully addressed. High-
dose radiation delivered precisely to small peripheral pul-
monary nodules will cause focal lung parenchyma fibrosis
that complicates interpretation of tumor response. At 3
months all tumors had responded to treatment, as seen by
a decrease in volume on CT imaging. However, at 12
months half of the lesions were obscured by radiation
fibrosis conforming to the high-dose radiation volume,
making further CT tumor response assessment difficult
[23,24]. In our experience, PET activity within irradiated
regions does not reliably indicate tumor recurrence
because the radiation response in the lung is itself PET
avid. Therefore, PET imaging was not routinely used to
follow patients in this study. Although biopsy could aid
response assessment, it was not recommended in these
typically frail patients in the absence of frank CT tumor
progression given the limited salvage treatment options
available. Consequently, when treated tumors appeared
to be obscured by radiation-induced fibrosis on serial CT
images (Figure 1), the tumors were considered locally
controlled and patients were observed with the under-
standing that the documentation of local recurrence
might be delayed.
High-dose thoracic radiotherapy delivered to small pul-
monary nodules, no matter how accurate, results in lim-
ited peritumoral lung damage and dysfunction. In the
absence of validated radiation pneumonitis risk parame-
ters for stereotactic radiosurgery, we chose to simply limit
the volume of lung receiving 15 Gy or greater. Although
we were able to limit this volume (V15 ranged from 3% to
Right upper lobe clinical stage IA NSCLC treatment planning CT (A), planned radiation dose distribution (B: the planning treat- ment volume is shown in orange and the 30 Gy isodose line in blue), and CT at 6 and 12 months post-treatment (C and D)  show progressive fibrosis in the treated volume that ultimately impedes CT evaluation of tumor response Figure 1
Right upper lobe clinical stage IA NSCLC treatment planning CT (A), planned radiation dose distribution (B: the planning treat-
ment volume is shown in orange and the 30 Gy isodose line in blue), and CT at 6 and 12 months post-treatment (C and D) 
show progressive fibrosis in the treated volume that ultimately impedes CT evaluation of tumor response.
A B
D C
Table 4: Tumor response per CT imaging
6 months (%) 12 months (%)
Complete Response 12 25
Partial Response 46 13
Obscured by Fibrosis* 42 50
Local Progression 0 12
* no evidence of progressionRadiation Oncology 2007, 2:39 http://www.ro-journal.com/content/2/1/39
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11% of total lung volume), Grade III pneumonitis
occurred in two patients, one at 4 weeks post-treatment
and the other at 10 months post-treatment. In both cases
pneumonitis onset was correlated with systemic therapy,
and one patient had had prior extensive conventional tho-
racic irradiation. Both patients recovered with steroid
treatment. No patients died of pneumonitis, lung fibrosis
or local recurrence; deaths in this trial were due to comor-
bid illness or preexisting metastatic disease progression.
Limited data are available evaluating the impact of stereo-
tactic radiosurgery on pulmonary function in patients
with small peripheral lung tumors (< 4 cm). Furthermore,
available findings are difficult to interpret because a large
fraction of lung cancer patients stop smoking just prior to
treatment; any deleterious effects of radiosurgery may be
offset by the early beneficial effects of smoking cessation
[25]. Ninety-five percent of the patients in the current trial
discontinued smoking in the distant past (>3 years prior
to treatment) or had never smoked. The mean percentage
of the total lung volume receiving a minimum of 15 Gy
was 7%. As might have been anticipated given the rela-
tively small volumes of peripheral lung irradiated to doses
capable of causing local lung dysfunction, small but statis-
tically significant 8% and 10% declines in the mean %
predicted DLCO were seen at 6 and 12 months, respec-
tively [26]. Regardless of the decline, no adverse clinical
effect was observed. Furthermore, the negative impact of
radiosurgery on diffusion capacity may be overestimated
in the current study as this effect is expected to be greater
in patients treated with prior conventional thoracic irradi-
ation or concurrent systemic therapy [27].
Critical central structure toxicity was not observed in this
trial. It is likely that toxicity was absent because we strictly
adhered to conservative maximum point dose limits for
critical central structures (Table 1). However, transient
mild-to-moderate chest wall pain typically lasting several
weeks was seen following treatment in the majority of
patients with lesions within 5 mm of the pleura. These
patients were treated conservatively with non-steroidal
anti-inflammatory medications or opioid analgesic com-
binations. Although it is tempting to limit the dose deliv-
ered to the chest wall in these patients, this would likely
result in additional local failures and is not recommended
at this time.
The current CyberKnife treatment approach requires the
implantation of fiducials to permit tumor targeting and
tracking. Fiducial placement results in a delay in therapy
while awaiting the resolution of procedure-related hemor-
rhage and fiducial fixation. Furthermore, the procedure
may result in pneumothorax, sometimes requiring tube
thoracostomy and a brief hospital stay [28]. Our institu-
tion has developed a technique for placing fiducials in or
near central and larger peripheral tumors via bronchos-
copy reducing the risk of pneumothorax [29]. However,
for the small peripheral tumors treated in this study
sophisticated navigation systems would be required to
place fiducials precisely in this manner. Fortunately,
ongoing research evaluating fiducial-less tracking will
likely result in technology that obviates the need for
peripheral fiducial placement in the near future [30].
Conclusion
Small peripheral lung tumors may be radically treated
with the CyberKnife frameless image-guided robotic radi-
osurgery system, resulting in encouraging early local con-
trol rates (92%) and minimal toxicity. The delivery of
hundreds of beams while continuously tracking respira-
tory tumor movement and adjusting beam directions
allows for highly conformal dose distributions with tight
margins (5 mm). It is likely that such treatment will result
in superior long term tumor control with acceptable tox-
icity and overall better treatment outcomes.
Abbreviations
BED Gy10: biologic effective tumor dose; CT: computed
tomography; DLCO: diffusing capacity of the lung for car-
bon monoxide; FEV1: forced expiratory volume in 1 sec;
GTV: gross tumor volume; Gy: Gray; NSCLC: non-small
cell lung cancer; PET: positron emission tomography; PFT:
pulmonary function tests; PTV: planning treatment vol-
ume; TLC: total lung capacity; V15: total lung volume
receiving 15 Gy or more.
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